Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
10.1046/j.1365-2125.2003.01767.x
Saved in:
Main Authors: | Lee, H.S., Goh, B.C., Fan, L., Khoo, Y.M., Wang, L., Lim, R., Ong, A.B., Chua, C. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/106218 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
by: Lee, H.S., et al.
Published: (2012) -
Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug
by: Tham, L.-S., et al.
Published: (2014) -
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers
by: Yong, W.-P., et al.
Published: (2014) -
Amineptine and midazolam dependence
by: Perera, I., et al.
Published: (2016) -
The use of midazolam and haloperidol in cancer patients at the end of life
by: Radha Krishna, L.K., et al.
Published: (2016)